Generic product of fixed dose combination product [Regulatives / Guidelines]

posted by nobody – 2017-05-16 21:17 (2327 d 07:35 ago) – Posting: # 17360
Views: 5,195

"...In this case two pharmacokinetics bridges may need to be built..."

Emphasis on may, I guess ;-)

Would strongly depend on the clinical data available for R(AB), I assume, if you have to go this way.

You could offer some food offerings to the oracle or some thousand bugs for an SA, to get the official answer to your questions. In fact I believe, you need both BE studies of your option 1 to pass plus an explanation for "no drift relevant" in practice, if you have clinical data only for combi of the monopreparations. FDC can be real pain...

Edit: Please don’t shout! [Helmut]

Kindest regards, nobody

Complete thread:

UA Flag
 Admin contact
22,763 posts in 4,775 threads, 1,627 registered users;
16 visitors (0 registered, 16 guests [including 10 identified bots]).
Forum time: 04:52 CEST (Europe/Vienna)

We should not speak so that it is possible
for the audience to understand us,
but so that it is impossible
for them to misunderstand us.    Quintilian

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz